FDA seeks support for reorganization of cancer programs, but debate continues.
In a letter, ASCO reaffirms its views on oncology consolidation at FDA.
Also in this 8-page issue: NCI advisors approve $15-million set-aside for laboratory testing on “reduced harm” tobacco products.
Board approves continuation of partnerships between minority institutions and cancer centers for research, training, and outreach.
Duke recruits Judd Moul as chief of urology.
Foundation offers funds for mesothelioma research.
Other NCI funding opportunities listed.
Trending Stories
- The faces of RIF: Staff members of NCI’s dissolved communications team gather for a farewell group photo
- George Sigounas named the first-ever chief science advisor at NCI
- A farewell post by an unidentified NCI employee triggers an accusation of “undermining the Trump administration”
- NIH eliminates the NCI Board of Scientific Advisors
Over its 28 year history, BSA shaped NCI-funded extramural science - Makary: Level of evidence is an artificial and dogmatic construct
- In The Headlines: Increasing incidence of early-onset cancer is “a paradigm shift oncology isn’t quite prepared for”